medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2013-4-82-91medsovet-990Research ArticleПрактикаPracticeЛечение ушибов головного мозгаTreatment of brain injuryТалыповА. Э.TalypovA. E.noemail@neicon.ruПетриковС. С.PetrikovS. S.noemail@neicon.ruПурасЮ. В.PurasYu. V.noemail@neicon.ruСолодовА. А.SolodovA. A.noemail@neicon.ruТитоваЮ. В.TitovaYu. V.noemail@neicon.ruНИИСП им. Н.В. Склифосовского, МоскваРоссияN.V. Sklifosofskiy Research Institute of Emergency Medical Aid, MoscowRussian Federation201330122013048291Copyright © Талыпов А.Э., Петриков С.С., Пурас Ю.В., Солодов А.А., Титова Ю.В., 20132013Талыпов А.Э., Петриков С.С., Пурас Ю.В., Солодов А.А., Титова Ю.В.Talypov A.E., Petrikov S.S., Puras Y.V., Solodov A.A., Titova Y.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/990

В статье представлен анализ современных методов хирургического и консервативного лечения ушибов головного мозга с учетом концепции первичных и вторичных повреждений головного мозга.

Modern methods of surgical and conservative treatment of primary and secondary brain injury are analyzed.

ушиб головного мозгавторичные повреждениялечениецитиколинbrain injurysecondary injurytreatmentciticolineReferencesЛекции по нейрохирургии под редакцией В.В. Крылова. М., Медицина, 2010; 318 с.Лекции по нейрохирургии под редакцией В.В. Крылова. М., Медицина, 2010; 318 с.Langlois J.A., Rutland-Brown W., Wald M.M. The epidemiology and impact of traumatic brain injury: a brief overview. J Head Trauma Rehabil. 2006; 21:375–8.Langlois J.A., Rutland-Brown W., Wald M.M. The epidemiology and impact of traumatic brain injury: a brief overview. J Head Trauma Rehabil. 2006; 21:375–8.Tagliaferri F., Compagnone C., Korsic M., Servadei F., Kraus J. A systematic review of brain injury epidemiology in Europe. Acta Neurochir (Wien) 2006; 148:255–68.Tagliaferri F., Compagnone C., Korsic M., Servadei F., Kraus J. A systematic review of brain injury epidemiology in Europe. Acta Neurochir (Wien) 2006; 148:255–68.Kraus M.F., Susmaras T., Caughlin P., Walker C.J., Sweeney J.A., Little D.M. White mater integrity and cognition in chronic traumaticbrain injury: a diffusion tensor imaging study. Brain. 2007; 130:2508–2519.Kraus M.F., Susmaras T., Caughlin P., Walker C.J., Sweeney J.A., Little D.M. White mater integrity and cognition in chronic traumaticbrain injury: a diffusion tensor imaging study. Brain. 2007; 130:2508–2519.Kontos H.A., Povlishock J.T. Oxygen radicals in brain injury. Cent Nerv Syst Trauma. 1986; 3:257–63.Kontos H.A., Povlishock J.T. Oxygen radicals in brain injury. Cent Nerv Syst Trauma. 1986; 3:257–63.Smith S.L., Andrus P.K., Zhang J.R., Hall E.D. Direct measurement of hydroxyl radicals, lipid peroxidation, and blood-brain barrier disruption following unilateral cortical impact head injury in the rat. J Neurotrauma. 1994; 11:393–404.Smith S.L., Andrus P.K., Zhang J.R., Hall E.D. Direct measurement of hydroxyl radicals, lipid peroxidation, and blood-brain barrier disruption following unilateral cortical impact head injury in the rat. J Neurotrauma. 1994; 11:393–404.Xiong Y., Gu Q., Peterson P.L., Muizelaar J.P., Lee C.P. Mitochondrial dysfunction and calcium perturbation induced by traumatic brain injury. J Neurotrauma. 1997;14:23–34.Xiong Y., Gu Q., Peterson P.L., Muizelaar J.P., Lee C.P. Mitochondrial dysfunction and calcium perturbation induced by traumatic brain injury. J Neurotrauma. 1997;14:23–34.Singh I.N., Sullivan P.G., Deng Y., Mbye L.H., Hall E.D. Time course of post-traumatic mitochondrial oxidative damage and dysfunction in a mouse model of focal traumatic brain injury: implications for neuroprotective therapy. J Cereb Blood Flow Metab. 2006; 26: 1407–18.Singh I.N., Sullivan P.G., Deng Y., Mbye L.H., Hall E.D. Time course of post-traumatic mitochondrial oxidative damage and dysfunction in a mouse model of focal traumatic brain injury: implications for neuroprotective therapy. J Cereb Blood Flow Metab. 2006; 26: 1407–18.Черепно-мозговая травма. Клиническое руководство под редакцией А.Н. Коновалова// М. Антидор., часть 2. 675 с.Черепно-мозговая травма. Клиническое руководство под редакцией А.Н. Коновалова// М. Антидор., часть 2. 675 с.Temple M., O’Leary D., Faden A. The role of glutamate receptors in the pathophysiology of traumatic brain injury. In: L Miller, R Hayes, JNewcomb, eds. HeadTrauma. New York, NY: John Wiley & Sons; 2001: 87-113.Temple M., O’Leary D., Faden A. The role of glutamate receptors in the pathophysiology of traumatic brain injury. In: L Miller, R Hayes, JNewcomb, eds. HeadTrauma. New York, NY: John Wiley & Sons; 2001: 87-113.Marklund N. Bakshi A. Castelbuono D.J. Conte V. McIntosh T.K. Evaluation of pharmacological treatment strategies in traumatic brain injury. Curr. Pharm. Des. 2006; 12: 1645–1680.Marklund N. Bakshi A. Castelbuono D.J. Conte V. McIntosh T.K. Evaluation of pharmacological treatment strategies in traumatic brain injury. Curr. Pharm. Des. 2006; 12: 1645–1680.Faden A.I. Pharmacologic treatment of acute traumatic brain injury. JAMA. 1996; 276: 569-570.Faden A.I. Pharmacologic treatment of acute traumatic brain injury. JAMA. 1996; 276: 569-570.Bullock M., Lyeth B., Muizelaar J. Current status of neuroprotection trials for traumatic brain injury: lessons from animal models and clinical studies. Neurosurgery. 1999; 45: 207-217.Bullock M., Lyeth B., Muizelaar J. Current status of neuroprotection trials for traumatic brain injury: lessons from animal models and clinical studies. Neurosurgery. 1999; 45: 207-217.Faden A.I. Neuroprotection and traumatic brain injury: theoretical option or realistic proposition. Curr. Opin. Neurol. 2002; 15: 707–712.Faden A.I. Neuroprotection and traumatic brain injury: theoretical option or realistic proposition. Curr. Opin. Neurol. 2002; 15: 707–712.Narayan R.K. Michel M.E. Ansell B. et.al. Clinical trials in head injury. J. Neurotrauma. 2002; 19: 503–557.Narayan R.K. Michel M.E. Ansell B. et.al. Clinical trials in head injury. J. Neurotrauma. 2002; 19: 503–557.Maas A.I. Marmarou A. Murray G.D. Teasdale S.G. Steyerberg E.W. Prognosis and clinical trial design in traumatic brain injury: the Impact study. J. Neurotrauma. 2007; 24: 232–238.Maas A.I. Marmarou A. Murray G.D. Teasdale S.G. Steyerberg E.W. Prognosis and clinical trial design in traumatic brain injury: the Impact study. J. Neurotrauma. 2007; 24: 232–238.Corwin H.L. Gettinger A. Rodriguez R.M. Pearl R.G. Gubler K.D. Enny C. Colton T. Corwin M.J. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit. Care Med. 1999;27:2346–2350.Corwin H.L. Gettinger A. Rodriguez R.M. Pearl R.G. Gubler K.D. Enny C. Colton T. Corwin M.J. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit. Care Med. 1999;27:2346–2350.Camacho-Arroyo I. Pasapera A.M. Cerbon M.A. Regulation of progesterone receptor gene expression by sex steroid hormones in the hypothalamus and the cerebral cortex of the rabbit. Neurosci. Lett. 1996; 214:25–28.Camacho-Arroyo I. Pasapera A.M. Cerbon M.A. Regulation of progesterone receptor gene expression by sex steroid hormones in the hypothalamus and the cerebral cortex of the rabbit. Neurosci. Lett. 1996; 214:25–28.Wang H. Lynch J.R. Song P. Yang H.J. Yates R.B. Mace B. Warner D.S. Guyton J.R. Laskowitz D.T. Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury. Exp. Neurol. 2007; 206:59–69.Wang H. Lynch J.R. Song P. Yang H.J. Yates R.B. Mace B. Warner D.S. Guyton J.R. Laskowitz D.T. Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury. Exp. Neurol. 2007; 206:59–69.Tanovic A., Alfaro V., Secades J. Citicoline in the treatment of traumatic brain injury Drugs on today, 2004 (Suppl. B): 1-18.Tanovic A., Alfaro V., Secades J. Citicoline in the treatment of traumatic brain injury Drugs on today, 2004 (Suppl. B): 1-18.Maas A.I. Neuroprotective agents in traumatic brain injury Drugs 2001; 10: 753-767.Maas A.I. Neuroprotective agents in traumatic brain injury Drugs 2001; 10: 753-767.Corwin H.L. Gettinger A. Rodriguez R.M. Pearl R.G. Gubler K.D. Enny C. Colton T. Corwin M.J. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit. Care Med. 1999;27:2346–2350.Corwin H.L. Gettinger A. Rodriguez R.M. Pearl R.G. Gubler K.D. Enny C. Colton T. Corwin M.J. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit. Care Med. 1999;27:2346–2350.Camacho-Arroyo I. Pasapera A.M. Cerbon M.A. Regulation of progesterone receptor gene expression by sex steroid hormones in the hypothalamus and the cerebral cortex of the rabbit. Neurosci. Lett. 1996; 214:25–28.Camacho-Arroyo I. Pasapera A.M. Cerbon M.A. Regulation of progesterone receptor gene expression by sex steroid hormones in the hypothalamus and the cerebral cortex of the rabbit. Neurosci. Lett. 1996; 214:25–28.Wang H. Lynch J.R. Song P. Yang H.J. Yates R.B. Mace B. Warner D.S. Guyton J.R. Laskowitz D.T. Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury. Exp. Neurol. 2007; 206:59–69.Wang H. Lynch J.R. Song P. Yang H.J. Yates R.B. Mace B. Warner D.S. Guyton J.R. Laskowitz D.T. Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury. Exp. Neurol. 2007; 206:59–69.Tanovic A., Alfaro V., Secades J. Citicoline in the treatment of traumatic brain injury Drugs on today, 2004 (Suppl. B): 1-18.Tanovic A., Alfaro V., Secades J. Citicoline in the treatment of traumatic brain injury Drugs on today, 2004 (Suppl. B): 1-18.Maas A.I. Neuroprotective agents in traumatic brain injury Drugs 2001; 10: 753-767.Maas A.I. Neuroprotective agents in traumatic brain injury Drugs 2001; 10: 753-767.

The authors declare that there are no conflicts of interest present.